Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome
Kidney International · 2023-09 · 104 (3) · 577-586
DOI: 10.1016/j.kint.2023.06.013 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Kidney International, 2023-09. Verfasst von Manuela Colucci und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nephrology, Translational Pediatrics and Clinical Genetics, Ospedale Pediatrico Bambino Gesù - Scientific Institute for Research and He…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Nephrotic Syndrome. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Fondazione Bambino Gesu Onlus, Ministero della Salute.
Abstract (Originalsprache)
B-cell depleting anti-CD20 monoclonal antibodies, such as rituximab, have proven efficacy in children with frequently-relapsing/steroid-dependent nephrotic syndrome (FR/SDNS). However, drug-free remission is variable and specific baseline markers predictive of relapse after anti-CD20 treatment are still being defined. To clarify these, we performed a bicentric observational study in a large cohort of 102 children and young adults with FR/SDNS treated with anti-CD20 monoclonal antibodies (rituximab and ofatumumab). Sixty-two patients (60.8%) relapsed during a 24-month period (median [interquartile range] relapse-free survival, 14.4 months [7.9-24.0]). A lower risk of relapse was significantly associated with an older age (over 9.8 years, hazard ratio, 0.44; 95% confidence interval, 0.26-0.74) and a higher risk of relapse was significantly associated with higher circulating levels of memory B cells (1.14; 1.09-1.32) at time of anti-CD20 infusion, independent of time elapsed from onset, previous anti-CD20 treatment, type of administered anti-CD20 monoclonal antibodies, and previous or maintenance oral immunosuppression. Patients younger than 9.8 years at anti-CD20 infusion had a subsequent higher recovery of total, transitional, mature-naïve and memory B-cell subsets independent of previous anti-CD20 treatment and maintenance immunosuppression. Significantly, younger age and higher circulating levels of memory B cells at time of anti-CD20 infusion were also independently associated with the recovery of memory B cells by linear mixed-effects modelling. Thus, both younger age and higher circulating levels of memory B cells at time of infusion are independently associated with a higher risk of relapse and an earlier recovery of memory B cells following anti-CD20 treatment in children with FR/SDNS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Nephrology, Translational Pediatrics and Clinical Genetics, Ospedale Pediatrico Bambino Gesù - Scientific Institute for Research and Health Care (IRCCS), Rome, Italy. Electronic address: manuela.colucci@op…
- Division of Nephrology, Dialysis and Transplantation, IRCCS Giannina Gaslini Children's Hospital, Genoa, Italy.
- Division of Nephrology and Renal Transplantation, Ospedale Pediatrico Bambino Gesù - IRCCS, Rome, Italy.
- B cell Unit, Immunology Research Area, Ospedale Pediatrico Bambino Gesù-IRCCS, Rome, Italy.
- Division of Epidemiology, Clinical Pathway and Clinical Risk Assessment, Ospedale Pediatrico Bambino Gesù - IRCCS, Rome, Italy.
- Cumming School of Medicine, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
Förderung
- Fondazione Bambino Gesu Onlus
- Ministero della Salute
Zitieren
APA
Colucci, M., Angeletti, A., Zotta, F., Carsetti, R., Lugani, F., Ravà, L., Ravani, P., Emma, F., Ghiggeri, G. M., & Vivarelli, M. (2023). Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome. Kidney International, 104(3), 577-586. https://doi.org/10.1016/j.kint.2023.06.013
Vancouver
Colucci M, Angeletti A, Zotta F, Carsetti R, Lugani F, Ravà L, et al. Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome. Kidney International. 2023;104(3):577-586. doi:10.1016/j.kint.2023.06.013
BibTeX
@article{Colucci2023,
author = {Colucci, Manuela and Angeletti, Andrea and Zotta, Federica and Carsetti, Rita and Lugani, Francesca and Ravà, Lucilla and Ravani, Pietro and Emma, Francesco and Ghiggeri, Gian Marco and Vivarelli, Marina},
title = {Age and memory B cells at baseline are associated with risk of relapse and memory B-cell reappearance following anti-CD20 treatment in pediatric frequently-relapsing/steroid-dependent nephrotic syndrome},
journal = {Kidney International},
year = {2023},
volume = {104},
number = {3},
pages = {577--586},
doi = {10.1016/j.kint.2023.06.013}
}
EUVIMED